Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation

Apremilast (Otezla(®)) is an oral small molecule phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease. While PDE4 inhibition overall is mechanistically understood, the effect of apremilast on the innate im...

Descripción completa

Detalles Bibliográficos
Autores principales: Meier-Schiesser, Barbara, Mellett, Mark, Ramirez-Fort, Marigdalia K., Maul, Julia-Tatjana, Klug, Annika, Winkelbeiner, Nicola, Fenini, Gabriele, Schafer, Peter, Contassot, Emmanuel, French, Lars E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657753/
https://www.ncbi.nlm.nih.gov/pubmed/34884681
http://dx.doi.org/10.3390/ijms222312878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657753/
https://www.ncbi.nlm.nih.gov/pubmed/34884681
http://dx.doi.org/10.3390/ijms222312878

Ejemplares similares